How to manage mandatory communication of Toxicological Risks?

About the webinar

When a toxicological risk is identified in a pharmaceutical product, whether during the manufacturing process or at the finished stage, it is crucial to promptly take appropriate action and formulate priority strategies to safeguard the safety and quality of the product.

In this webinar, we will delve into essential strategies for accurately assessing and interpreting such risks, effectively reporting and communicating findings, investigating root causes, and implementing corrective measures to mitigate and prevent potential harm to both patients and the environment.

Watch the webinar on demand

Meet Patricia, our Toxicology Coordinator at the QbD Group. She’s got quite the academic background. She graduated  inChemical engineering with a Master’s degree in Advanced Therapies and Biotechnological Innovation. She’s currently pursuing a PhD in Toxicology and Pharmacology at Complutense University of Madrid. Patricia has a wealth of experience in microbiological research, including cell cultures, recombinant drugs, and physico-chemical lab work. She’s skilled at characterizing molecules, identifying impurities, and conducting CMC analysis. Additionally, she’s an expert at writing reports for regulatory agencies and has received GMP trainin g. She’s also experienced in EMA and FDA audits.